3C-like-proteinase inhibitors- Pipeline Insight, 2022
This report can be delivered to the clients within 24 hours
DelveInsight’s, “3C-like-proteinase inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in 3C-like-proteinase inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
3C-like-proteinase inhibitors: Overview
3C-like-proteinase is a cysteine protease that is excised from polyproteins by its own proteolytic activity and forms a homodimer with one active site per subunit. 3CL pro reportedly recognizes the residues from P4 to P1 on the N-terminal side and P1? on the C-terminal side of the cleavage sites, based on the consensus sequences around the processing sites in the SARS-CoV polyproteins and the extensive mutagenesis analyses of the N-terminal autoprocessing site. 3C?like proteases (3CLpros) from CoVs (also called main proteases) are essential for viral replication and are also involved in polyprotein cleavage and immune regulation, making them attractive and effective targets for the development of antiviral drugs. 3-chymotrypsin-like protease (3CL pro) is considered to be a promising drug target. Various studies are going on to study this protein in order to identify therapeutics against the SARS-CoV in particular and other pathogenic coronaviruses. A number of patented inhibitors with promising clinical potential have been developed through different methods.
Report Highlights
This segment of the 3C-like-proteinase inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
3C-like-proteinase inhibitors Emerging Drugs
Further product details are provided in the report……..
3C-like-proteinase inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different 3C-like-proteinase inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
3C-like-proteinase inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses 3C-like-proteinase inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging 3C-like-proteinase inhibitors drugs.
3C-like-proteinase inhibitors Report Insights
Current Scenario and Emerging Therapies:
DelveInsight’s, “3C-like-proteinase inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in 3C-like-proteinase inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
3C-like-proteinase inhibitors: Overview
3C-like-proteinase is a cysteine protease that is excised from polyproteins by its own proteolytic activity and forms a homodimer with one active site per subunit. 3CL pro reportedly recognizes the residues from P4 to P1 on the N-terminal side and P1? on the C-terminal side of the cleavage sites, based on the consensus sequences around the processing sites in the SARS-CoV polyproteins and the extensive mutagenesis analyses of the N-terminal autoprocessing site. 3C?like proteases (3CLpros) from CoVs (also called main proteases) are essential for viral replication and are also involved in polyprotein cleavage and immune regulation, making them attractive and effective targets for the development of antiviral drugs. 3-chymotrypsin-like protease (3CL pro) is considered to be a promising drug target. Various studies are going on to study this protein in order to identify therapeutics against the SARS-CoV in particular and other pathogenic coronaviruses. A number of patented inhibitors with promising clinical potential have been developed through different methods.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence 3C-like-proteinase inhibitors R&D. The therapies under development are focused on novel approaches for 3C-like-proteinase inhibitors.
This segment of the 3C-like-proteinase inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
3C-like-proteinase inhibitors Emerging Drugs
- Masitinib: AB Science
- PF-07304814: Pfizer
Further product details are provided in the report……..
3C-like-proteinase inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different 3C-like-proteinase inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on 3C-like-proteinase inhibitors
- Phases
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical
- Molecule Type
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
3C-like-proteinase inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses 3C-like-proteinase inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging 3C-like-proteinase inhibitors drugs.
3C-like-proteinase inhibitors Report Insights
- 3C-like-proteinase inhibitors Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing 3C-like-proteinase inhibitors drugs?
- How many 3C-like-proteinase inhibitors drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for 3C-like-proteinase inhibitors?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the 3C-like-proteinase inhibitors therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for 3C-like-proteinase inhibitors and their status?
- What are the key designations that have been granted to the emerging drugs?
- AB Science
- Pfizer
- Aligos Therapeutics
- Array BioPharma
- Eli Lilly and Company
- SOM Biotech
- Cortexyme
- Masitinib
- PF-07304814
- ALG-097111
- Prexasertib
- Eravacycline
- Research programme: small molecules
Introduction
Executive Summary
3C-LIKE-PROTEINASE INHIBITORS: OVERVIEW
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
3C-LIKE-PROTEINASE INHIBITORS – DELVEINSIGHT’S ANALYTICAL PERSPECTIVE
In-depth Commercial Assessment
3C-like-proteinase inhibitors companies’ collaborations, Licensing, Acquisition -Deal Value Trends
3C-LIKE-PROTEINASE INHIBITORS COLLABORATION DEALS
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Masitinib: AB Science
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II/III)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
PF-07304814: Pfizer
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
ALG-097111: Aligos Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
3C-LIKE-PROTEINASE INHIBITORS KEY COMPANIES
3C-LIKE-PROTEINASE INHIBITORS KEY PRODUCTS
3C-LIKE-PROTEINASE INHIBITORS- UNMET NEEDS
3C-LIKE-PROTEINASE INHIBITORS- MARKET DRIVERS AND BARRIERS
3C-LIKE-PROTEINASE INHIBITORS- FUTURE PERSPECTIVES AND CONCLUSION
3C-LIKE-PROTEINASE INHIBITORS ANALYST VIEWS
3C-LIKE-PROTEINASE INHIBITORS KEY COMPANIES
Appendix
Executive Summary
3C-LIKE-PROTEINASE INHIBITORS: OVERVIEW
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
3C-LIKE-PROTEINASE INHIBITORS – DELVEINSIGHT’S ANALYTICAL PERSPECTIVE
In-depth Commercial Assessment
3C-like-proteinase inhibitors companies’ collaborations, Licensing, Acquisition -Deal Value Trends
3C-LIKE-PROTEINASE INHIBITORS COLLABORATION DEALS
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Masitinib: AB Science
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II/III)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
PF-07304814: Pfizer
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
ALG-097111: Aligos Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
3C-LIKE-PROTEINASE INHIBITORS KEY COMPANIES
3C-LIKE-PROTEINASE INHIBITORS KEY PRODUCTS
3C-LIKE-PROTEINASE INHIBITORS- UNMET NEEDS
3C-LIKE-PROTEINASE INHIBITORS- MARKET DRIVERS AND BARRIERS
3C-LIKE-PROTEINASE INHIBITORS- FUTURE PERSPECTIVES AND CONCLUSION
3C-LIKE-PROTEINASE INHIBITORS ANALYST VIEWS
3C-LIKE-PROTEINASE INHIBITORS KEY COMPANIES
Appendix
LIST OF TABLES
Table 1 Total Products for 3C-like-proteinase inhibitors
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for 3C-like-proteinase inhibitors
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for 3C-like-proteinase inhibitors
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for 3C-like-proteinase inhibitors
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products